Brief: Bimzelx Two-Year Data At AAD Showed Potential To Eliminate Draining Tunnels In Hidradenitis Suppurativa
07/03/2025 13:35
March 7 (Reuters) - Ucb SA UCB.BR: BIMZELX® (BIMEKIZUMAB-BKZX) TWO-YEAR DATA AT AAD SHOWED POTENTIAL TO ELIMINATE DRAINING TUNNELS IN HIDRADENITIS SUPPURATIVA, AND REDUCTION IN DISEASE BURDEN Source text: ID:nPnpcCTva Further company coverage: UCB.BR (Reuters.Briefs@thomsonreuters.com)
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside